Swiss pharma giants Roche and Novartis fight over patent in US court
Roche claims there was a patent infringement on the lung drug Esbriet.
Copyright 2016 The Associated Press. All Rights Reserved.
This content was published on
1 minute
Keystone-SDA/ds
Swiss pharmaceutical giant Roche is taking its rival Novartis to court in the US. Roche subsidiary Genentech has filed suit in New Jersey District Court against Novartis subsidiary Sandoz for patent infringement on the lung drug Esbriet.
This is according to the indictment filed on Monday, cited by the Keystone-SDA news agency. The case was first reported by Reuters.
Genentech complains that Sandoz started selling a generic version of Esbriet in mid-May 2022, even though Sandoz had not applied for a license. As a result, Genentech’s patent had been infringed, it said. The generic displacement of Esbriet has caused significant financial harm to the Roche subsidiary, it said. Esbriet had sales of more than $740 million (CHF650 million) in the U.S. alone in 2021.
Genentech is now seeking unspecified damages including lost profits and/or an appropriate royalty. Sandoz is also expected to pay the legal costs.
Genentech’s Esbriet is used to treat idiopathic pulmonary fibrosis (IPF), a fatal chronic lung disease with no cure. Roche earned over $1 billion worldwide from Esbriet in 2021, but sales fell to under $820 million in 2022, according to Reuters.
What factors should be taken into account when inheriting Swiss citizenship abroad?
Should there be a limit to the passing on of Swiss citizenship? Or is the current practice too strict and it should still be possible to register after the age of 25?
Swiss rivers and lakes remain low as dry weather persists
This content was published on
The start of the year has been far too dry for Switzerland's rivers and lakes. Some of them have fallen to record levels, and the situation is not about to improve, warned MeteoNews on Tuesday.
EFTA and Ukraine sign updated free trade agreement
This content was published on
The European Free Trade Association (EFTA), of which Switzerland is a member, and Ukraine signed an updated free trade agreement in Kyiv on Tuesday.
Switzerland hires US lobby firm to secure access to AI chips
This content was published on
Switzerland's State Secretariat for Economic Affairs (SECO) has hired a lobbying firm in the United States to help Switzerland gain full access to artificial intelligence chips.
Six Swiss cities to bid for 2030 ‘Capital of Culture’ title
This content was published on
The Swiss cities of Aarau, Bellinzona, Lugano, Schaffhausen, Thun and Zug are competing to become Switzerland's "Capital of Culture" in 2030.
This content was published on
The Swiss Financial Market Supervisory Authority (FINMA) is calling for legal changes to enable it to intervene early on if banks violate corporate governance rules.
François Bocion painting fetches record at Swiss auction
This content was published on
The oil painting La chasse aux grèbes by Lausanne artist François Bocion (1828-1890) fetched a record CHF270,250 ($315,530) at an auction in Basel in early April, the highest price ever paid for one of his works.
This content was published on
One in six homes in Switzerland is located in a zone threatened by natural hazards, a new study by Zürcher Kantonalbank (ZKB) has revealed.
This content was published on
The prices of owner-occupied properties continued to rise in the first three months of 2025. But large regional disparities remain.
Swiss Solidarity charity launches appeal for earthquake victims in Myanmar and Thailand
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has launched an appeal for donations for victims of the recent earthquake in Myanmar and Thailand.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis seals deal to license high-priced cancer drug
This content was published on
Swiss pharma giant Novartis has finalised a deal to allow generic production of its patented drug nilotinib to treat chronic myeloid leukemia.
This content was published on
Switzerland takes the top spot in total patent filings per capita to the European Patent Office. Roche and ABB lead the field among Swiss companies.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.